Artiva Biotherapeutics (NASDAQ:ARTV) COO Jennifer Bush Sells 8,790 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) COO Jennifer Bush sold 8,790 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $79,197.90. Following the completion of the sale, the chief operating officer owned 337,920 shares in the company, valued at $3,044,659.20. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Artiva Biotherapeutics Stock Down 7.3%

NASDAQ ARTV traded down $0.67 during midday trading on Tuesday, hitting $8.55. The company had a trading volume of 844,679 shares, compared to its average volume of 581,930. The stock has a market cap of $211.36 million, a price-to-earnings ratio of -2.42 and a beta of 2.86. The firm has a fifty day simple moving average of $8.32 and a two-hundred day simple moving average of $5.65. Artiva Biotherapeutics, Inc. has a fifty-two week low of $1.47 and a fifty-two week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). As a group, equities analysts predict that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Large investors have recently modified their holdings of the stock. Prelude Capital Management LLC acquired a new position in shares of Artiva Biotherapeutics during the third quarter worth approximately $41,000. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Artiva Biotherapeutics during the first quarter worth approximately $131,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Artiva Biotherapeutics during the fourth quarter worth approximately $91,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Artiva Biotherapeutics during the first quarter worth approximately $139,000.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ARTV shares. Wedbush lifted their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Needham & Company LLC lifted their target price on shares of Artiva Biotherapeutics from $18.00 to $41.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Cantor Fitzgerald boosted their price target on shares of Artiva Biotherapeutics from $10.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.